NovaBridge Biosciences Cash and Restricted Cash
NovaBridge Biosciences (NBP) had Cash and Restricted Cash of $210.63 million as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-04-07
- 2023-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.20B CNY.
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.31B CNY.
- 2022-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.71B CNY.
- 2021-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.52B CNY.
CNY
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2023-12-31 | 2.20B CNY 20-F · filed 2024-04-30 |
| 2022-12-31 | 3.31B CNY 20-F · filed 2024-04-30 |
| 2022-06-30 | 3.71B CNY 6-K · filed 2022-11-10 |
| 2021-12-31 | 3.52B CNY 20-F · filed 2024-04-30 |
| 2021-06-30 | 4.35B CNY 6-K · filed 2022-11-10 |
| 2020-12-31 | 4.76B CNY 20-F · filed 2024-04-30 |
| 2020-09-30 | 2.96B CNY 6-K · filed 2021-02-05 |
| 2019-12-31 | 1.19B CNY 20-F · filed 2023-05-01 |
| 2019-09-30 | 1.28B CNY 6-K · filed 2021-02-05 |
| 2018-12-31 | 1.68B CNY 20-F · filed 2022-04-29 |
| 2017-12-31 | 412.71M CNY 20-F · filed 2021-04-28 |
| 2016-12-31 | 64.08M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2025-12-31 | $210.63M 20-F · filed 2026-04-07 | |
| 2025-09-30 | $228.06M 6-K · filed 2025-12-18 | |
| 2025-06-30 | $165.40M 6-K · filed 2025-10-06 | |
| 2024-12-31 | $68.26M 20-F · filed 2026-04-07 | |
| 2024-09-30 | $79.33M 6-K · filed 2025-12-18 | |
| 2024-06-30 | $151.96M 6-K · filed 2025-10-06 | |
| 2023-12-31 | $310.67M 20-F · filed 2026-04-07 | $309.91M 20-F · filed 2024-04-30 |
| 2022-12-31 | $475.37M 20-F · filed 2026-04-07 | $480.02M 20-F · filed 2023-05-01 |
| 2022-06-30 | $554.02M 6-K · filed 2022-11-10 | |
| 2021-12-31 | $552.67M 20-F · filed 2025-04-03 | $552.93M 20-F · filed 2022-04-29 |
| 2020-12-31 | $746.76M 20-F · filed 2022-04-29 | $729.32M 20-F · filed 2021-04-28 |
| 2020-09-30 | $435.96M 6-K · filed 2021-02-05 | |
| 2019-12-31 | $182.88M 20-F · filed 2021-04-28 | $171.41M 20-F · filed 2020-04-29 |
| 2018-12-31 | $241.45M 20-F · filed 2020-04-29 |